At CeQur, our leadership team drives the passion and focus of our company to bring simpler, more effective options to people with diabetes. Diabetes is complicated enough, so CeQur is dedicated to providing options that are easier to use and incorporate into the life of those who need insulin.
Executive Chairman & Chairman of the Board
Director of Schroder & Co Bank SA
Past President & CEO of Atrium Innovations
Executive Vice President of Regulatory Affairs
Investment Director, Excalibur
Independent Healthcare Professional
Managing Partner & President, Endeavour
The board supports CeQur by advising the company on product development, clinical trial design, educational programming for professionals and people with diabetes, and other medically-related activities.
Endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet, Dr. Bergenstal is a Clinical Professor in the Department of Medicine at the University of Minnesota. He served as President, Medicine & Science of the American Diabetes Association in 2010, and was named the ADA's Outstanding Physician Clinician of the Year in 2007. He received his medical degree and endocrine training from the University of Chicago where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983. Dr. Bergenstal's clinical research has focused on glucose control and diabetes complications. He serves as a Principal Investigator of three NIH trials: the DCCT/EDIC in T1D, the ACCORD follow-up, and GRADE study in T2D. He studies the effective utilization of insulin therapy and glucose monitoring, as well as other new technologies to improve glucose control and clinical outcomes. Dr. Bergenstal teaches nationally and internationally on the importance of developing new models of care built around patient-centered team care and has published over 150 peer reviewed scientific articles.
Head of the Research Institute at the Diabetes Centre Mergentheim (FIDAM) for 17 years and an Adjunct Professor for Clinical Psychology at the University of Bamberg, Germany. He received his Masters degree in Psychology and is a certified “Psychological Psychotherapist” and “Psychodiabetologist” by the German Diabetes Association. His research interests include behavioral modification, development and evaluation of diabetes self-management-programs, acute emotional effects of hypoglycemia, depression and diabetes. Professor Hermanns has authored numerous publications, as well as reviewed for scientific journals in the diabetes field. Professor Hermanns' professional memberships have included: Past-Chair of the Psychosocial Aspects of Diabetes Study Group (PSAD) of EASD, and the Diabetes and Psychology board within the DDG as well as the Diabetes Depression Dialogue. He is also member of the international advisory board of the DAWN 2 study.
Diabetes educator for over thirty years. As a clinical nurse specialist and education coordinator, Ms. Hinnen currently works at Mid America Diabetes Associates as coordinator of a multidisciplinary team, focusing program efforts on a three day comprehensive self-management course that serves nearly 1,000 people with diabetes per year. She is involved extensively with the American Association of Diabetes Educators, having served as their national President from 1993 to 1994, and was awarded their prestigious Distinguished Service Award in 2001. Ms. Hinnen has also served on the National Board of Directors for the American Diabetes Association, and as an editor for Diabetes Spectrum Journal. Her faculty positions are with the Pharmacy of Department at the University of Kansas, and Graduate Nursing Department at Wichita State University and the Physicians Assistant Program at Wichita State. Ms. Hinnen was inducted as a Fellow of American Academy of Nursing in 2003.
Dr. David Horwitz is President of DLH Biomedical Consulting LLC, which focuses on assisting small and large companies with medical device development, clinical trial and regulatory strategy, protocol development, and advisory board management and facilitation. He previously served as Global Chief Medical Officer of the Johnson and Johnson Diabetes Institute. Prior to this, he was Vice President, Worldwide Clinical Affairs & Evidence Based Medicine at LifeScan, Inc., a Johnson & Johnson company. During his time at LifeScan, Dr. Horwitz had at various times been responsible for Clinical Research, Medical Affairs, Regulatory Affairs, and Advocacy & Professional Affairs. David has an extensive career in diabetes and endocrinology. His clinical and academic career includes faculty positions in the medical schools at the University of Chicago and the University of Illinois, where he was Clinical Professor of Medicine and Adjunct Associate Professor of nutrition and medical dietetics. His prior industry positions include Vice President for Professional Affairs at Baxter International, Executive Vice President at SciClone pharmaceuticals, and Senior Vice President for technology at Advanced Tissue Sciences. Dr. Horwitz obtained his bachelor’s degree at Harvard University, majoring in Chemistry and Physics, and has an M.D. and Ph.D. (in physiology) from the University of Chicago and an MBA from the Lake Forest Graduate School of Management. He is a Board-Certified internist and endocrinologist, and a Fellow of the American College of Physicians. He has published over 100 articles in scientific and clinical journals, primarily in the areas of diabetes and metabolism. He has served as industry representative on the Clinical Chemistry and Toxicology advisory panel of the U.S. Food and Drug Administration, and at various times has served as a consultant to FDA and NIH.
Director of Clinical Research at the International Diabetes Center, where testing has occurred on almost every new diabetes medication and device on the market today. She has developed protocols and has served as project director on numerous research trials and co-authored articles and abstracts in the specialty areas of hypertension, cardiology, nephrology and diabetes. Ms. Johnson is a member of the steering committee and a Project Leader for the NIH multi-center study entitled ACCORD, "Action to Control Cardiovascular Risk in Diabetes." She has also had industry experience as a clinical research monitor, ensuring accuracy of data reported to sponsoring companies and adherence to FDA regulations. Ms. Johnson is a member of the American Diabetes Association and speaks on diabetes topics in the local, state and national arena.
Professor of Diabetes and Metabolism at King's College London School of Medicine Guy's Hospital, London, UK. Dr. Pickup received both his medical training and PhD in biochemical endocrinology at the University of Oxford. After a fellowship at the Massachusetts General Hospital, Boston, and an appointment at the Hammersmith Hospital in London he moved to Guy's Hospital. He has also been Visiting Professor in the Dept of Physics at the University of Strathclyde, Glasgow since 2005. He has a long-standing interest in the development and application of novel technology for the improved management of diabetes, starting from the development of insulin pump therapy through to in vivo glucose sensors. He has authored numerous peer reviewed publications, and is the co-editor of the 'Textbook of Diabetes' as well as the 'Handbook of Diabetes' (Blackwell Publishers). He is an expert adviser on diabetes to the National Institute for Health and Clinical Excellence.
CeQur Medical Director and consultant for diabetes drug development. He trained in Internal Medicine and Diabetology at the Universities Goettingen and Marburg, Germany, and Geneva, Switzerland. In 1993, he joined Lilly Germany as Clinical Research Physician for Diabetes where he was responsible for the clinical development of insulin lispro (Humalog). From 1996 to 1998 Dr. Trautmann was a Global Physician in the Endocrine Therapeutic Area with responsibilities for early phase development of novel therapeutic approaches in the areas of obesity and type 2 diabetes treatments. Thereafter he moved to the Lilly Research Laboratories in Hamburg and coordinated early phase clinical programs. He worked on several programs in the areas of insulin, insulin delivery, and GLP-1. Under his leadership exenatide (Byetta and Bydureon) was approved as treatment for Diabetes in Europe, the USA, and Japan. Dr Trautmann is a member of several national and international associations for Diabetes and Endocrine Research and has authored numerous publications in this field.
Co-owner and CEO of Diabetes Network, Inc., an American Diabetes Association-recognized program. Ms. Valentine is the recipient of the Roche/Zitter Diabetes Disease Management Award, the Outstanding Diabetes Educator of the Year Award, and is also the 2006 recipient of the Distinguished Service Award from the American Association of Diabetes Educators. She received her Master of Science in Nursing degree from the University of Oklahoma College of Nursing. She holds faculty appointments with the University of New Mexico College of Nursing, School of Medicine, and College of Pharmacy. Ms. Valentine is a member of the Advanced Practice Advisory Board to the New Mexico Board of Nursing and serves as Past-President of the New Mexico Leadership Council of the American Diabetes Association. She has published widely on the topic of diabetes for both professionals and patients, including "Diabetes: the New Type 2" (2008, New York: Tarcher/Penguin).
We would also like to express our appreciation for the many healthcare professionals and consultants that have and will continue to help us along our journey.
CeQur Corporation, with offices in Marlborough, Massachusetts and Wales, UK, is a growing company dedicated to the design, manufacture and commercialization of simple 3-day wearable insulin delivery devices, designed specifically for the needs of people with diabetes. We are always looking for the best talent to join the CeQur team. We value and reward teamwork, initiative, leadership, commitment and responsibility and provide challenging and stimulating career opportunities that will create a new market of simple insulin infusion. We offer a competitive compensation package including excellent medical benefits and a close knit supportive work environment.